| Primary |
| Product Used For Unknown Indication |
60.0% |
| Anaesthesia |
33.3% |
| Prophylaxis |
6.7% |
|
| Blood Pressure Decreased |
25.0% |
| Dysarthria |
25.0% |
| Erythema |
25.0% |
| Pruritus |
25.0% |
|
| Secondary |
| Drug Use For Unknown Indication |
20.9% |
| Anaesthesia |
18.8% |
| Product Used For Unknown Indication |
14.7% |
| Induction Of Anaesthesia |
13.4% |
| General Anaesthesia |
6.6% |
| Premedication |
3.9% |
| Sedation |
3.3% |
| Antibiotic Prophylaxis |
2.5% |
| Epilepsy |
2.0% |
| Femur Fracture |
2.0% |
| Prophylaxis |
2.0% |
| Status Epilepticus |
2.0% |
| Preoperative Care |
1.8% |
| Surgery |
1.5% |
| Spinal Anaesthesia |
0.9% |
| Anaesthetic Premedication |
0.8% |
| Escherichia Bacteraemia |
0.8% |
| Escherichia Infection |
0.8% |
| Prophylaxis Against Gastrointestinal Ulcer |
0.8% |
| Resuscitation |
0.8% |
|
| Renal Failure Acute |
19.3% |
| Anaphylactic Shock |
18.8% |
| Cytolytic Hepatitis |
5.7% |
| Shock |
5.7% |
| Tachycardia |
5.7% |
| Rash |
5.1% |
| Cardiac Arrest |
4.5% |
| Respiratory Failure |
4.5% |
| Cardio-respiratory Arrest |
4.0% |
| Circulatory Collapse |
3.4% |
| Hypotension |
2.8% |
| Rash Maculo-papular |
2.8% |
| Septic Shock |
2.8% |
| Toxic Skin Eruption |
2.8% |
| Erythema |
2.3% |
| Generalised Erythema |
2.3% |
| Toxic Epidermal Necrolysis |
2.3% |
| Injection Site Thrombosis |
1.7% |
| Stevens-johnson Syndrome |
1.7% |
| Ventricular Fibrillation |
1.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
46.3% |
| Anaesthesia |
7.6% |
| Drug Use For Unknown Indication |
6.5% |
| Coronary Artery Bypass |
6.0% |
| Prophylaxis |
5.0% |
| Cardiopulmonary Bypass |
4.9% |
| Induction Of Anaesthesia |
3.1% |
| Hypertension |
2.7% |
| Pain |
2.6% |
| Sedation |
2.3% |
| Thrombosis Prophylaxis |
1.8% |
| Bradycardia |
1.7% |
| Aortic Valve Replacement |
1.5% |
| Psoas Abscess |
1.5% |
| Fluid Replacement |
1.3% |
| Pain Prophylaxis |
1.3% |
| Catheterisation Cardiac |
1.1% |
| Infection Prophylaxis |
1.0% |
| Respiratory Tract Infection |
1.0% |
| Induction And Maintenance Of Anaesthesia |
0.9% |
|
| Injury |
14.2% |
| Pain |
7.5% |
| Renal Failure Acute |
7.5% |
| Anxiety |
6.0% |
| Stress |
6.0% |
| Renal Failure |
5.2% |
| Septic Shock |
5.2% |
| Unevaluable Event |
5.2% |
| Anhedonia |
4.5% |
| Fear |
4.5% |
| Rhabdomyolysis |
4.5% |
| Tachyarrhythmia |
4.5% |
| Hypotension |
3.7% |
| Tachycardia |
3.7% |
| Cerebrovascular Accident |
3.0% |
| Circulatory Collapse |
3.0% |
| Emotional Distress |
3.0% |
| Pancreatitis Acute |
3.0% |
| Rash |
3.0% |
| Thrombocytopenia |
3.0% |
|
| Interacting |
| General Anaesthesia |
32.2% |
| Product Used For Unknown Indication |
15.3% |
| Drug Use For Unknown Indication |
10.2% |
| Femur Fracture |
6.8% |
| Pain Prophylaxis |
6.8% |
| Haemodialysis |
3.4% |
| Hypertension |
3.4% |
| Prophylaxis |
3.4% |
| Ureteral Meatotomy |
3.4% |
| Anaesthesia |
1.7% |
| Depressive Symptom |
1.7% |
| Drug Therapy |
1.7% |
| Induction And Maintenance Of Anaesthesia |
1.7% |
| Induction Of Anaesthesia |
1.7% |
| Nausea |
1.7% |
| Pain |
1.7% |
| Parathyroid Gland Operation |
1.7% |
| Surgery |
1.7% |
|
| Drug Interaction |
33.3% |
| Renal Failure Acute |
22.2% |
| Renal Tubular Necrosis |
11.1% |
| Respiratory Failure |
11.1% |
| Sedation |
11.1% |
| Serotonin Syndrome |
11.1% |
|
